These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 11970753)

  • 21. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial.
    De Placido S; Gallo C; De Laurentiis M; Bisagni G; Arpino G; Sarobba MG; Riccardi F; Russo A; Del Mastro L; Cogoni AA; Cognetti F; Gori S; Foglietta J; Frassoldati A; Amoroso D; Laudadio L; Moscetti L; Montemurro F; Verusio C; Bernardo A; Lorusso V; Gravina A; Moretti G; Lauria R; Lai A; Mocerino C; Rizzo S; Nuzzo F; Carlini P; Perrone F;
    Lancet Oncol; 2018 Apr; 19(4):474-485. PubMed ID: 29482983
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    Rose C
    Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.
    Hole S; Pedersen AM; Hansen SK; Lundqvist J; Yde CW; Lykkesfeldt AE
    Int J Oncol; 2015 Apr; 46(4):1481-90. PubMed ID: 25625755
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE
    Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine and clinical endpoints of exemestane as neoadjuvant therapy.
    Miller WR; Dixon JM
    Cancer Control; 2002; 9(2 Suppl):9-15. PubMed ID: 11965226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer.
    Lu Q; Liu Y; Long BJ; Grigoryev D; Gimbel M; Brodie A
    Breast Cancer Res Treat; 1999 Sep; 57(2):183-92. PubMed ID: 10598045
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of aromatase inhibitors on learning and memory and modulation of hippocampal dickkopf-1 and sclerostin in female mice.
    Zameer S; Vohora D
    Pharmacol Rep; 2017 Dec; 69(6):1300-1307. PubMed ID: 29128813
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systematic review of aromatase inhibitors in the first-line treatment for hormone sensitive advanced or metastatic breast cancer.
    Riemsma R; Forbes CA; Kessels A; Lykopoulos K; Amonkar MM; Rea DW; Kleijnen J
    Breast Cancer Res Treat; 2010 Aug; 123(1):9-24. PubMed ID: 20535542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Overview of the pharmacology of the aromatase inactivator exemestane.
    Brueggemeier RW
    Breast Cancer Res Treat; 2002 Jul; 74(2):177-85. PubMed ID: 12186378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug safety evaluation of exemestane.
    Lintermans A; Neven P; Paridaens R
    Expert Opin Drug Saf; 2011 May; 10(3):473-87. PubMed ID: 21428848
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preliminary data from ongoing adjuvant aromatase inhibitor trials.
    Goss PE
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4397s-4401s; discussion 4411s-4412s. PubMed ID: 11916231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aromatase Inhibitor-Mediated Downregulation of INrf2 (Keap1) Leads to Increased Nrf2 and Resistance in Breast Cancer.
    Khatri R; Shah P; Guha R; Rassool FV; Tomkinson AE; Brodie A; Jaiswal AK
    Mol Cancer Ther; 2015 Jul; 14(7):1728-37. PubMed ID: 25976679
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adjuvant use of aromatase inhibitors in postmenopausal women with breast cancer.
    Michaud LB
    Am J Health Syst Pharm; 2005 Feb; 62(3):266-73. PubMed ID: 15719584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations between genetic variants and the effect of letrozole and exemestane on bone mass and bone turnover.
    Oesterreich S; Henry NL; Kidwell KM; Van Poznak CH; Skaar TC; Dantzer J; Li L; Hangartner TN; Peacock M; Nguyen AT; Rae JM; Desta Z; Philips S; Storniolo AM; Stearns V; Hayes DF; Flockhart DA
    Breast Cancer Res Treat; 2015 Nov; 154(2):263-73. PubMed ID: 26536870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast.
    Miller WR
    Endocr Relat Cancer; 1999 Jun; 6(2):187-95. PubMed ID: 10731108
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
    Howell A; Howell SJ; Clarke R; Anderson E
    J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antiaromatase agents: evolving role in adjuvant therapy.
    Jones SE
    Clin Breast Cancer; 2002 Apr; 3(1):33-42. PubMed ID: 12020394
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Preclinical evaluation of aromatase inhibitors antitumor activity].
    Auvray P; Bichat F; Genne P
    Bull Cancer; 2000 Dec; 87 Spec No():7-22. PubMed ID: 11250604
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aromatase destabilizer: novel action of exemestane, a food and drug administration-approved aromatase inhibitor.
    Wang X; Chen S
    Cancer Res; 2006 Nov; 66(21):10281-6. PubMed ID: 17079446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonsteroidal and steroidal aromatase inhibitors in breast cancer.
    Hamilton A; Volm M
    Oncology (Williston Park); 2001 Aug; 15(8):965-72; discussion 972, 977-9. PubMed ID: 11548977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.